This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Antibody Engineering & Therapeutics US

Hurry! $500 Savings Ends In:

  • 00
  • 00
  • 00
  • 00
December 4 - 8, 2022
Marriott Marquis San DiegoDelivered as a Hybrid Event

Karen Silence, PhD
Head Preclinical Product Development at Argenx


I worked for four years at the university of Brussels developing the Nanobody platform which lead to the establishment of Ablynx, where I was the first employee. I was inventor and project leader for Caplacizumab, the first and only Nanobody approved today.
After that I joined argenx where I was inventor and project leader for ARGX-110, ARGX-117, ARGX-119 and ARGX-120. I work since 6 years as an independent consultant and supported argenx, Citryll, Catalym and Staten with the preclinical development of their antibodies. At this moment I am head of all late stage discovery programs at argenx as a consultant and advisor for Fair Journey Biologics.

Agenda Sessions

  • Healthy Volunteer Data with ARGX-117, A Sweeping Anti-C2 Antibody